Literature DB >> 28267530

Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients.

Johannes Grueneisen1, Lino Morris Sawicki2, Axel Wetter3, Julian Kirchner2, Sonja Kinner3, Bahriye Aktas4, Michael Forsting3, Verena Ruhlmann5, Lale Umutlu3.   

Abstract

OBJECTIVES: To investigate the diagnostic value of different MR sequences and 18F-FDG PET data for whole-body restaging of breast cancer patients utilizing PET/MRI.
METHODS: A total of 36 patients with suspected tumor recurrence of breast cancer based on clinical follow-up or abnormal findings in follow-up examinations (e.g. CT, MRI) were prospectively enrolled in this study. All patients underwent a PET/CT and subsequently an additional PET/MR scan. Two readers were instructed to identify the occurrence of a tumor relapse in subsequent MR and PET/MR readings, utilizing different MR sequence constellations for each session. The diagnostic confidence for the determination of a malignant or benign lesion was qualitatively rated (3-point ordinal scale) for each lesion in the different reading sessions and the lesion conspicuity (4-point ordinal scale) for the three different MR sequences was additionally evaluated.
RESULTS: Tumor recurrence was present in 25/36 (69%) patients. All three PET/MRI readings showed a significantly higher accuracy as well as higher confidence levels for the detection of recurrent breast cancer lesions when compared to MRI alone (p<0.05). Furthermore, all three PET/MR sequence constellations showed comparable diagnostic accuracy for the identification of a breast cancer recurrence (p>0.05), yet the highest confidence levels were obtained, when all three MR sequences were used for image interpretation. Moreover, contrast-enhanced T1-weighted VIBE imaging showed significantly higher values for the delineation of malignant and benign lesions when compared to T2w HASTE and diffusion-weighted imaging.
CONCLUSION: Integrated PET/MRI provides superior restaging of breast cancer patients over MRI alone. Facing the need for appropriate and efficient whole-body PET/MR protocols, our results show the feasibility of fast and morphologically adequate PET/MR protocols. However, considering an equivalent accuracy for the detection of breast cancer recurrences in the three PET/MR readings, the application of contrast-agent and the inclusion of DWI in the study protocol seems to be debatable.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  18F-FDG; Breast cancer; PET/MRI; Protocol optimization; Whole-body restaging

Mesh:

Substances:

Year:  2017        PMID: 28267530     DOI: 10.1016/j.ejrad.2016.12.019

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  8 in total

1.  Integrated versus separate reading of F-18 FDG-PET/CT and MRI for abdominal malignancies - effect on staging outcomes and diagnostic confidence.

Authors:  Lisa A Min; Wouter V Vogel; Max J Lahaye; Monique Maas; Maarten L Donswijk; Erik Vegt; Miranda Kusters; Henry J Zijlmans; Katarzyna Jóźwiak; Sander Roberti; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2019-05-22       Impact factor: 5.315

2.  What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?

Authors:  Diomidis Botsikas; Ilias Bagetakos; Marlise Picarra; Ana Carolina Da Cunha Afonso Barisits; Sana Boudabbous; Xavier Montet; Giang Thanh Lam; Ismini Mainta; Anastasia Kalovidouri; Minerva Becker
Journal:  Eur Radiol       Date:  2018-09-28       Impact factor: 5.315

3.  Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent diffusion coefficients and maximum standardized uptake values.

Authors:  Michiro Sasaki; Mitsuhiro Tozaki; Kazunori Kubota; Wakana Murakami; Daisuke Yotsumoto; Yasuaki Sagara; Yasuyo Ohi; Shunichi Oosako; Yoshiaki Sagara
Journal:  Jpn J Radiol       Date:  2017-11-20       Impact factor: 2.374

4.  Hybrid 18F-FDG-PET/MRI Measurement of Standardized Uptake Value Coupled with Yin Yang 1 Signature in Metastatic Breast Cancer. A Preliminary Study.

Authors:  Concetta Schiano; Monica Franzese; Katia Pane; Nunzia Garbino; Andrea Soricelli; Marco Salvatore; Filomena de Nigris; Claudio Napoli
Journal:  Cancers (Basel)       Date:  2019-09-26       Impact factor: 6.639

5.  Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.

Authors:  Nils Martin Bruckmann; Julian Kirchner; Janna Morawitz; Lale Umutlu; Ken Herrmann; Ann-Kathrin Bittner; Oliver Hoffmann; Svjetlana Mohrmann; Marc Ingenwerth; Benedikt M Schaarschmidt; Yan Li; Andreas Stang; Gerald Antoch; Lino M Sawicki; Christian Buchbender
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

6.  What is the Diagnostic Performance of 18F-FDG-PET/MRI in the Detection of Bone Metastasis in Patients with Breast Cancer?

Authors:  Filiz Çelebi
Journal:  Eur J Breast Health       Date:  2019-10-01

7.  Towards fast whole-body PET/MR: Investigation of PET image quality versus reduced PET acquisition times.

Authors:  Maike E Lindemann; Vanessa Stebner; Alexander Tschischka; Julian Kirchner; Lale Umutlu; Harald H Quick
Journal:  PLoS One       Date:  2018-10-30       Impact factor: 3.240

8.  Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients.

Authors:  Nils Martin Bruckmann; Lino M Sawicki; Julian Kirchner; Ole Martin; Lale Umutlu; Ken Herrmann; Wolfgang Fendler; Ann-Kathrin Bittner; Oliver Hoffmann; Svjetlana Mohrmann; Frederic Dietzel; Marc Ingenwerth; Benedikt M Schaarschmidt; Yan Li; Bernd Kowall; Andreas Stang; Gerald Antoch; Christian Buchbender
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-24       Impact factor: 9.236

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.